ReviewCancer journal (Sudbury, Mass.)
Intestinal microbiome and lymphoma development.
Review in Cancer journal (Sudbury, Mass.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 40 citations in OpenAlex.
- Oral, not gut microbiota diversity, reflects the inflammation and neoplasia in patients with uveitis and vitreoretinal lymphoma.Journal of ophthalmic inflammation and infection · 2025Article
- Dissecting causal links between gut microbiota, inflammatory cytokines, and DLBCL: a Mendelian randomization study.Blood advances · 2024Article
- Characteristics and prognostic value of gut microbiota in follicular lymphoma.Oncology letters · 2024Article
- Gut Microbiota's role in lipoma development: evidence from mendelian randomization.Frontiers in genetics · 2024Article
- The impact of gut microbial signals on hematopoietic stem cells and the bone marrow microenvironment.Frontiers in immunology · 2024Review
- Defining the Role of the Gut Microbiome in the Pathogenesis and Treatment of Lymphoid Malignancies.International journal of molecular sciences · 2023Review
- Common themes in antimicrobial and anticancer drug resistance.Frontiers in microbiology · 2022Review
- Bacterial Infection and Non-Hodgkin B-Cell Lymphoma: Interactions between Pathogen, Host and the Tumor Environment.International journal of molecular sciences · 2021Review
- Potential Application of Combined Therapy with Lectins as a Therapeutic Strategy for the Treatment of Bacterial Infections.Antibiotics (Basel, Switzerland) · 2021Review
- Antibiotics: Conventional Therapy and Natural Compounds with Antibacterial Activity-A Pharmaco-Toxicological Screening.Antibiotics (Basel, Switzerland) · 2021Review
- Emerging Roles for the Gut Microbiome in Lymphoid Neoplasms.Clinical Medicine Insights. Oncology · 2021Review
- The Microbiome as a Component of the Tumor Microenvironment.Advances in experimental medicine and biology · 2020Review
- Antibiotics, cancer risk and oncologic treatment efficacy: a practical review of the literature.Ecancermedicalscience · 2020Review
- Use of Antibiotics and Risk of Cancer: A Systematic Review and Meta-Analysis of Observational Studies.Cancers · 2019Article
- Cadaverine, a metabolite of the microbiome, reduces breast cancer aggressiveness through trace amino acid receptors.Scientific reports · 2019Article
- Glyphosate-based herbicides and cancer risk: a post-IARC decision review of potential mechanisms, policy and avenues of research.Carcinogenesis · 2018Review
- Relationship of the mucosal microbiota to gastrointestinal inflammation and small cell intestinal lymphoma in cats.Journal of veterinary internal medicine · 2018Article
- Heavy Chain Disease of the Small Bowel.Current gastroenterology reports · 2018Review
- When human cells meet bacteria: precision medicine for cancers using the microbiota.American journal of cancer research · 2018Review
- A Preclinical Model for the ATLL Lymphoma Subtype With Insights Into the Role of Microenvironment in HTLV-1-Mediated Lymphomagenesis.Frontiers in microbiology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The intestinal microbiota and gut immune system must communicate to maintain a balance between tolerance and activation. Our immune system protects us from pathogenic microbes at the same time that our bodies are host to trillions of microbes, symbionts, mutualists, and some that are essential to human health. Since there is such a close interaction between the immune system and the intestinal microbiota, it is not surprising that some lymphomas such as mucosal-associated lymphoid tissue lymphoma have been shown to be caused by the presence of certain bacteria. Animal models have played an important role in elucidating the causation and establishing the mechanism of bacteria-induced mucosal-associated lymphoid tissue lymphoma. In this review, we discuss different ways that animal models have been applied to investigate links between the gut microbiota and lymphoma and have helped to reveal the mechanisms of microbiota-induced lymphoma. Although there is a paucity of published studies demonstrating the interplay between the microbiota and lymphoma development, we believe that the connection is real and that it can be exploited in the future to enhance our understanding of causation and to improve the prognosis and treatment of lymphoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.